MLAB mesalabs.com: Forward P/S Multiple

Graphic logo of Mesa Labs Corp (MLAB)

Mesa Laboratories, Inc. (MLAB) is developing a recurring sales model for consumables, ensuring high margins. The forward P/S ratio confirms this growth, with the 0.30 metric serving as the target level. Financial stability is based on plants in the US and Europe, while strict FDA standards and patents for sterilization systems create significant barriers to entry for new market players.

mesalabs.com - MLAB Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for Mesa Laboratories Corp. (MLAB)

- current price and projected stock value:
Stock Price Mesa Labs|MLAB - Average Forecast Price
- company stock capitalization data:
Market Capitalization Mesa Laboratories Corp.|MLAB - Business Value
- issuer book value statistics:
Book Value per Share Mesa Labs|MLAB - Book Valuation of Business|Market Capitalization to Book Value Ratio mesalabs.com|MLAB - Cumulative Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital Mesa Laboratories, Inc.|MLAB - Long-Term Debt to Capital|Short-Term Debt to Equity Mesa Laboratories, Inc.|MLAB - Company Debts|Debt to Book Value Mesa Laboratories Corp.|MLAB - Company Long-Term Loans and Borrowings|Company Short-Term Debts Mesa Labs|Quick Liquidity mesalabs.com
- financial results and valuation multiples details:
MLAB - Annual Net Income|Future Profit Mesa Laboratories, Inc.|MLAB - P/E Multiple|Forward P/E Multiple Mesa Labs Corp|MLAB - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Mesa Laboratories Corp.|MLAB - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Mesa Labs|MLAB - Net earnings per share for the last 12 months|Quarterly EPS earnings growth mesalabs.com|MLAB - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Mesa Laboratories, Inc.
- sales volume and revenue indicators:
MLAB - Company Sales Volume|Company Future Sales Volume Mesa Labs|MLAB - Market Cap to Sales Volume|Price-to-Projected Revenue Ratio Mesa Laboratories Corp.
Summary company analytics:Mesa Labs (MLAB)
Product sample of Mesa Laboratories, Inc.

To minimize risks during long-term asset ownership, it is necessary to align market value with the actual potential for cash flow generation. For Mesa Laboratories, Inc. (MLAB), which holds exclusive rights to sterilization indicators, the forward price-to-sales ratio reflects the relationship between the current price and projected sales, making it possible to determine whether the premium for its technological monopoly is justified or if the asset is speculatively overvalued.

Key competitors

Forward P/S Multiple ABT (Abbott)|Thermo Fisher Scientific Inc. (TMO) - Market Cap to Future Revenue Ratio|GE Healthcare Corp - Forward P/S Multiple|MTD (Mettler Toledo Inc) - Market Cap to Projected Revenue|WAT: Forward P/S Multiple|TECH - Market Cap to Expected Sales Ratio|BRKR (Bruker) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Azenta Inc (AZTA)|Forward P/S Multiple VREX|Forward P/S Multiple Semler (SMLR)|Price-to-Projected Revenue Ratio Butterfly Network, Inc. BFLY|quantum-si.com - Price-to-Projected Revenue Ratio|NNOX: Forward Price-to-Revenue Multiple|Forward Price to Sales QTRX (Quanterix Corp.)|MASS: Forward P/S Multiple|Market Cap to Future Revenue Ratio CapsoVision (CV)|Price-to-Projected Revenue Ratio MaxCyte, Inc.|RPID - Projected Price to Revenue|Forward Price-to-Revenue Multiple SEER (Seer)|Forward P/S Multiple Hyperfine Inc (HYPR)|Forward P/S Multiple FONR (FONAR Corp)|Market Cap to Expected Sales Ratio Daxor Corp (DXR)|MDAI - Price-to-Projected Revenue Ratio|Future Price to Revenue VIVS|Aclarion, Inc. (ACON) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Akoya Biosciences, Inc.|THMO (ThermoGenesis Holdings Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Talis Biomedical Corp TLIS|Price-to-Projected Revenue Ratio T2 Biosystems, Inc. (TTOO)